A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.
Also called NCT02851849
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 148 participants
- Sponsor
- Ligand Pharmaceuticals
- Registry
-
NCT02851849
-
- Other papers using this trial's data
- Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02851849. Randomized; double masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- LGD-6972-5 mg
- Intervention (Drug)
- LGD-6972-10 mg
- Intervention (Drug)
- LGD-6972-15 mg
- Intervention (Other)
- Placebo
- Lead sponsor
- Ligand Pharmaceuticals
Record details
- Record id
cardio:ct-nct02851849- Content hash
ffb30537cca95876b71cd06ce01efe9801ca186e17bcb161de57870241827559